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Perseghin, Gianluca, Guido Lattuada, Massimo
Danna, Lucia Piceni Sereni, Paola Maffi, Francesco De
Cobelli, Alberto Battezzati, Antonio Secchi, Alessan-
dro Del Maschio, and Livio Luzi. Insulin resistance, in-
tramyocellular lipid content, and plasma adiponectin in pa-
tients with type 1 diabetes. Am J Physiol Endocrinol Metab
285: E1174–E1181, 2003. First published August 21, 2003;
10.1152/ajpendo.00279.2003.—Insulin resistance is a key
pathogenic factor of type 2 diabetes (T2DM); in contrast, in
type 1 diabetes (T1DM) it is considered a secondary alter-
ation. Increased intramyocellular lipid (IMCL) content accu-
mulation and reduced plasma adiponectin were suggested to
be pathogenic events of insulin resistance in T2DM. This
study was designed to assess whether IMCL content and
plasma adiponectin were also associated with the severity of
insulin resistance in T1DM. We studied 18 patients with
T1DM, 7 older and overweight/obese patients with T2DM,
and 15 nondiabetic, insulin-resistant offspring of T2DM par-
ents (OFF) and 15 healthy individuals (NOR) as appropriate
control groups matched for anthropometric features with
T1DM patients by means of the euglycemic hyperinsulinemic
clamp combined with the infusion of [6,6-2H2]glucose and 1H
magnetic resonance spectroscopy of the calf muscles. T1DM
and T2DM patients showed reduced insulin-stimulated glu-
cose metabolic clearance rate (MCR: 5.1  0.6 and 3.2  0.8
ml  kg1  min1) similar to OFF (5.3  0.4 ml  kg1  min1)
compared with NOR (8.5  0.5 ml  kg1  min1, P  0.001).
Soleus IMCL content was increased in T1DM (112  15 AU),
T2DM (108  10 AU) and OFF (82  13 AU) compared with
NOR (52  7 AU, P  0.05) and the result was inversely
proportional to the MCR (R2  0.27, P  0.001); an associa-
tion between IMCL content and Hb A1c was found only in
T1DM (R2  0.57, P  0.001). Fasting plasma adiponectin
was reduced in T2DM (7  1 g/ml, P  0.01) and OFF (11 
1 g/ml, P  0.03) but not in T1DM (25  6 g/ml), whose
plasma level was increased with respect to both OFF (P 
0.03) and NOR (16  2 g/ml, P  0.05). In conclusion, in
T1DM, T2DM, and OFF, IMCL content was associated with
insulin resistance, demonstrating that IMCL accretion is a
marker of insulin resistance common to both primary genet-
ically determined and secondary metabolic (chronic hyper-
glycemia) alterations. The increased adiponectin levels in
insulin-resistant patients with T1DM, in contrast to the
reduced levels found in patients with T2DM and in OFF,
demonstrated that the relationship of adiponectin to insulin
resistance in humans is still unclear.
intramyocellular triglyceride content; leptin; magnetic reso-
nance spectroscopy
INSULIN RESISTANCE typically characterizes type 2 diabe-
tes (T2DM) and prediabetic states and is the promi-
nent feature of the metabolic syndrome (8). Even if the
primary metabolic defect of type 1 diabetes (T1DM) is
considered to be insulin deficiency, a number of studies
have suggested that a certain degree of insulin resis-
tance is also present in patients with T1DM (9, 10, 11,
26, 31, 47). An increased intramyocellular triglyceride
(IMCL) content has been hypothesized to be the patho-
genic event responsible for the development of insulin
resistance in T2DM and in the insulin resistance syn-
drome (28). The noninvasive measurement of IMCL
using 1H magnetic resonance spectroscopy (MRS) at
1.5 Tesla field strength (6, 42), which allows one to
measure separately lipids in fat cells and lipids located
in the cytoplasm of muscle cells, demonstrated a strong
inverse relationship between insulin sensitivity and
IMCL content in normal humans (25), individuals with
increased risk of developing T2DM (14, 23, 27, 35), and
patients with obesity and T2DM (41). For all this
evidence, the concept of IMCL storage as a local
marker of whole body insulin resistance has been rec-
ognized (39).
Adiponectin, a plasma protein exclusively produced
by the adipose tissue, has recently been suggested to be
an insulin-sensitizing agent involved in the pathogen-
esis of insulin resistance (1, 5, 20, 44, 46). Whether an
inappropriate accretion of the IMCL content and re-
duced circulating adiponectin levels might also be in-
volved in the pathogenesis of insulin resistance in
patients with T1DM is unknown. This study was de-
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signed to assess the relationships of insulin resistance
to IMCL content and plasma adiponectin levels in
patients with T1DM. T1DM patients had to be com-
pared with T2DM patients, but because the anthropo-
metric features of these two groups of diabetic individ-
uals were completely different, a more appropriate
comparison was also made with tightly matched insu-
lin-resistant first-degree offspring of parents with
T2DM (OFF), who are known to be characterized by
alterations of insulin action similar to those of their
parents (17, 32, 35), and with normal healthy (NOR)
subjects.
METHODS
Subjects
Eighteen patients with T1DM and seven patients with
recently diagnosed T2DM recruited at the outpatient service
of the Diabetes Unit of the Istituto Scientifico H San Raffaele,
and 30 healthy individuals with (OFF) or without (NOR)
first-degree relatives with T2DM recruited at the Center of
Nutrition/Metabolism, participated in the study. Among the
18 T1DM patients, five had proliferative retinopathy, four
had nonproliferative retinopathy, and three had sensory-
motor nuropathy. None of the patients with T2DM had signs
of retinopathy, neuropathy, or nephropathy, but they were
obviously older and fatter than the patients with T1DM.
Individuals in the control groups (OFF and NOR) were se-
lected to be tightly comparable to T1DM for anthropometric
features and lifestyle habits. Habitual physical activity was
assessed using a questionnaire (2). Body weights were stable
for 6–12 mo. The three women with T2DM were in meno-
pause. Two women of those with T1DM were taking oral
steroidal contraception (OSC), and because of the possible
effects of OSC on insulin sensitivity and IMCL content (36)
two of the women in the OFF and NOR groups were selected
because they were in OSC treatment. The anthropometric
characteristics of the subjects are summarized in Table 1. All
subjects were in good health as assessed by medical history,
physical examination, hematological analysis, and urinaly-
sis. Informed consent was obtained from all subjects after
explanation of the purposes, nature, and potential risks of
the study. The protocol was approved by the Ethics Commit-
tee of the Istituto Scientifico H San Raffaele.
Experimental Protocol
Subjects were instructed to consume an isocaloric diet and
to abstain from exercise activity for 3 wk before the studies.
Women were studied between days 3 and 8 of the menstrual
cycle. Subjects were studied by means of the euglycemic
hyperinsulinemic clamp to assess whole body insulin sensi-
tivity after a 10-h overnight fast and during the insulin
clamp. Within 2–3 days, they were studied by means of 1H
MRS to assess IMCL content. The MRS session was per-
formed in the Division of Diagnostic Radiology of the Istituto
Scientifico H San Raffaele between 0700 and 0900 after a
10-h overnight fast.
Euglycemic hyperinsulinemic clamp. Patients with T1DM
were instructed to undergo the usual therapeutic regimen
the day before the studies and to abstain from taking any
subcutaneous insulin in the morning of the clamp and MRS
studies. Patients with T2DM were not taking any drug and
were only on a diet treatment. Subjects were admitted to the
Metabolic Unit of the Division of Internal Medicine I of the
Istituto Scientifico H San Raffaele the night before the clamp
study. During the night, when capillary glucose concentra-
tion exceeded 11 mmol/l, an exogenous insulin infusion (0.1
mU  kg1  min1) was started. Nondiabetic patients were
admitted at 0700 after a 10-h overnight fast. A Teflon cath-
eter was inserted into an antecubital vein for infusions, and
an additional one was inserted retrogradely into a wrist vein
for blood sampling. The hand was kept in a heated box
throughout the experiment to allow sampling of arterialized
venous blood. A bolus of 5 mg/kg body wt of [6,6-2H2]glucose
was administered to the OFF and NOR groups; the bolus
administered to T1DM patients was adjusted, as previously
described (19), according to the fasting plasma glucose con-
Table 1. Anthropometric and laboratory characteristics of the study groups
T2DM OFF T1DM Normals
n (M/F) 4M/3F 8M/7F 9M/9F 8M/7F
Age, yr 563* 272 312 263
BMI, kg/m2 28.51.7* 21.40.7 22.50.7 22.00.8
Diabetes duration, yr 11 202
Daily insulin dose, U/day 423
Physical activity index 7.60.5 8.30.2 8.00.3 8.00.4
Creatinine, mol/l 9711 725 837 746
Creatinine clearance, ml/s 1.610.45 1.670.25 1.770.23 1.690.18
Total cholesterol, mmol/l 6.010.58* 4.960.28 4.970.24 4.450.13
HDL-cholesterol, mmol/l 1.400.12 1.430.09 1.720.11 1.280.06
LDL-cholesterol, mmol/l 3.320.29* 3.000.25 2.860.26 2.810.14
Triglycerides, mmol/l 2.820.26* 1.130.16 0.920.11 0.820.10
Hb A1c, % 7.80.3* 5.20.3 8.60.4* 5.40.7
Basal Insulin Basal Insulin Basal Insulin Basal Insulin
Plasma glucose, mmol/l 6.40.1* 5.20.1 5.00.1 4.90.0 12.71.4* 6.40.5* 5.10.1 4.90.1
Plasma FFA, mmol/l 0.820.07* 0.110.01* 0.670.05* 0.050.00 0.650.13*‡ 0.130.03* 0.420.06 0.050.01
Plasma free insulin, pmol/l 9112* 42135 383 36710 458 41725 363 36713
Plasma C-peptide, nmol/l 0.940.15* 0.610.07* 0.420.04 0.210.03 ND ND 0.430.04 0.170.02
Values are means  SE. BMI, body mass index; FFA, free fatty acids; T2DM, patients with type 2 diabetes; OFF, first-degree relatives of
T2DM; T1DM, patients with type 1 diabetes. LDL-cholesterol was calculated using Friedewald’s formula. Basal indicates the fasting state;
Insulin indicates the last 30 min of the insulin clamp; ND, 0.015 nmol/l. *P  0.01 vs. Normals. ‡Morning of the magnetic resonance
spectroscopy study, without overnight insulin infusion, fasting plasma venous FFA was 0.93  0.11 mmol/l (P  0.001 vs. Normals).
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centration. Immediately after administration of the bolus, a
continuous infusion (0.05 mg  kg body wt1  min1) of [6,6-
2H2]glucose (MassTrace, Woburn, MA) was started. Blood
samples for postabsorptive plasma glucose, total cholesterol,
HDL-cholesterol, triglycerides, free fatty acids, insulin, C-
peptide, tumor necrosis factor- receptor-2 (-TNFR2), lep-
tin, and adiponectin were performed in duplicate in the
postabsorptive condition. After a 150-min tracer equilibra-
tion period, a euglycemic hyperinsulinemic clamp was per-
formed as previously described (35, 36). Insulin was infused
at 40 mU  m2  min1 to reach a plasma insulin concentra-
tion of 350 pmol/l, and plasma glucose concentration was
kept at 5 mmol/l for an additional 150 min by means of a
variable infusion of 20% dextrose. When fasting hyperglyce-
mia was present in T1DM and T2DM patients, the plasma
glucose concentration was allowed to drop to the euglycemic
level, and thereafter the attempt was made to maintain a
plasma glucose concentration of 5 mmol/l as in the normo-
glycemic individuals. Blood samples for plasma hormones,
substrates, and tracer enrichment were drawn every 15 min
throughout the study.
1H MRS. 1H MRS was performed on a GE Signa 1.5
Tesla scanner (General Electric Medical Systems, Milwau-
kee, WI) using a conventional linear extremity coil as
previously described (35, 36). Briefly, high resolution T1-
weighted images of the right calf were obtained before the
spectroscopic acquisitions to localize the voxel of interest
for the 1H spectroscopy study. Voxel shimming was exe-
cuted to optimize the homogeneity of the magnetic field
within the specific volume of interest. Two 1H spectra were
collected from a 15  15  15-mm volume within the soleus
and tibialis anterior muscles, respectively. A PRESS pulse
sequence (TR  2,000 ms and TE  60 ms) was used, and
128 averages were accumulated for each spectrum, with a
final acquisition time of 4.5 min. The water signal was
suppressed during the acquisition, as it would have dom-
inated the other metabolite’s peak signals of interest. A
third 1H spectrum of a triglyceride solution inside a glass
sphere, positioned within the extremity coil next to the
calf, was also obtained during the same session to acquire
an external standard in the same conditions as the sub-
ject’s spectra. Postprocessing of the data, executed with
the Sage/IDL software (General Electric Medical Systems),
consisted of high-pass filtering, spectral apodization, zero
filling, Fourier transformation, and phasing of the spectra.
The integral of the area under the peak was calculated
using a Marquardt fitting with Lorentzian functions of the
peaks of interest. The integral of the methylene signal
(-CH2) at 1.35 ppm was used to calculate IMCL content
expressed in arbitrary units (AU) as a ratio with the
integral of the peak of the external standard times 1,000.
Analytical Procedures
Plasma glucose was measured with a Beckman glucose
analyzer (35). Plasma free fatty acids and plasma total cho-
lesterol, HDL-cholesterol, and triglycerides were measured
as previously described (35). LDL-cholesterol was calculated
using the Friedewald formula. Plasma free insulin was mea-
sured with microparticle enzyme immunoassay technology
(36) with no cross-reactions with proinsulin, C-peptide, and
glucagon (IMx Insulin assay; Abbott Laboratories, Rome,
Italy), and C-peptide was measured by RIA with a double
antibody (36). Plasma leptin concentrations were deter-
mined, as previously described (36), by RIA with a human kit
(Linco Research, St. Charles, MO) following the manufactur-
er’s assay protocol [intra- and interassay coefficients of vari-
ation (CV) 5 and 10%, respectively]. -TNFR2 was mea-
sured with an enzyme immunoassay (Immunotech; Beckman
Coulter, Marseille, France) following the manufacturer’s rec-
ommendations (intra- and interassay CV 3% and 5%, re-
spectively). Plasma adiponectin was measured using a com-
mercially available RIA kit (catalog no. HADP-61HK; Linco
Research) (21). The intra- and interassay CV for adiponectin
were 4  1 and 14  3%, respectively. The titers of the
immunologic markers of T1DM (anti-GAD, -ICA, and -IA2
antibodies) were measured as previously described (33). The
[2H2]glucose enrichment was measured by GC-MS as previ-
ously described (3).
Calculations
Glucose kinetics were calculated using Steele’s equations
for the nonsteady state (40). Steady state of plasma dideu-
terated glucose enrichments was reached in the study groups
during both the end of the equilibration period and the last
30 min of the insulin clamp. Endogenous glucose production
was calculated by subtracting the glucose infusion rate from
the rate of glucose appearance measured with the isotope
tracer technique. Total body glucose uptake was determined
during the clamp by adding the rate of residual endogenous
glucose production to the rate of glucose disappearance. The
metabolic clearance rate (MCR) was calculated to normalize
the glucose turnover rate to the plasma glucose concentra-
tion.
Statistical Analysis
All data are presented as means  SE. Comparisons
among groups were performed using the analysis of variance
and Tukey’s post hoc testing when appropriate. Simple re-
gression analysis was performed to assess relationships be-
tween variables.
RESULTS
Anthropometric and Laboratory Characteristics
of Study Groups
Anthropometric parameters of the study subjects are
summarized in Table 1. T1DM, OFF, and NOR sub-
jects were tightly matched for age, sex, body mass
index, and physical activity index; in contrast, T2DM
subjects were older and fatter.
Glucose Metabolism in Postabsorptive State
and During Insulin Clamp
Postabsorptive plasma glucose levels (Table 1) and
endogenous glucose production rates were increased in
T1DM (4.15  0.34 mg  kg1  min1; P  0.001) com-
pared with T2DM, OFF, and NOR groups (2.59  0.08,
2.19  0.06, and 2.39  0.11 mg  kg1  min1, respec-
tively). During the insulin clamp, plasma glucose con-
centration was maintained at the fasting level in
T2DM, OFF, and NOR subjects, whereas in T1DM
patients it was allowed to drop to euglycemic levels,
and thereafter it was clamped at a slightly higher level
than in the OFF and NOR groups (Table 1; P  0.05).
During the clamp, T1DM patients showed a certain
degree of insulin resistance with respect to the sup-
pression of the endogenous glucose production (69  5
vs. 79  11, 86  4, and 88  8% in T1DM vs. T2DM,
OFF, and NOR, respectively; P  0.05), even if it must
E1176 IMCL CONTENT IN T1DM
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be stated that the insulin dose used in the present
experimental protocol (40 mU  m2  min1) was proba-
bly too high to detect more subtle differences at the
level of the endogenous glucose production. Also, the
insulin-stimulated glucose metabolism was impaired
in T1DM (5.31  0.46 mg  kg1  min1, P  0.01) as
well as in T2DM (3.19  0.78 mg  kg1  min1, P 
0.01) and OFF subjects (4.76  0.40 mg  kg1  min1,
P  0.01) compared with the NOR group (7.54  0.37
mg  kg1  min1). Because fasting and clamp plasma
glucose levels were slightly but significantly higher in
T1DM and T2DM patients compared with the other
groups, estimates of insulin-stimulated glucose meta-
bolic rates had to be corrected for the circulating glu-
cose levels. The glucose MCR was therefore calculated
and found to be similarly reduced in the T1DM, T2DM,
and OFF groups compared with the NOR group (5.1 
0.6, 3.51  1.0, and 5.3  0.4 ml  kg1  min1, respec-
tively, vs. 8.5  0.5 ml  kg1  min1, P  0.001; Fig. 1,
top).
IMCL Content
1H MRS of the calf muscle showed that IMCL con-
tent was increased in T1DM (112  15 AU), T2DM
(108  10 AU), and OFF (82  13 AU) compared with
NOR subjects (52  7 AU, P  0.05; Fig. 1, middle) in
the soleus muscle, whereas in the tibialis anterior only
T1DM patients showed a significant increment of
IMCL (40  15 AU vs. 23  3, 19  5, and 13  2 AU,
P  0.05; Fig. 1, middle).
Plasma Adiponectin, Leptin and Soluble
-TNFR2 Concentrations
Plasma adiponectin levels were reduced in T2DM
(7  1 g/ml, P  0.01 vs. NOR) and OFF subjects
(11  1 g/ml, P  0.03 vs. NOR) but not in T1DM
patients (25  6 g/ml), whose plasma level was in-
creased compared with the T2DM (P 0.01), OFF (P
0.03), and NOR groups (16 2 g/ml, P 0.05; Fig. 2).
At the end of the clamp study, plasma adiponectin
concentration showed a nonsignificant decrement of
5  5, 6  9, 7  10, and 6  9% in the T2DM, OFF,
T1DM, and NOR subjects, respectively. The lack of a
significant decrement is in contrast to the work by Yu
et al. (48), but this discrepancy is likely due to the
different duration (300-min vs. 150-min clamps in the
present study) and to the different insulin dose (80 vs.
40 mU  m2  min1 in the present study) designed for
these clamp studies. Fasting plasma leptin concentra-
tions (5.0  1.3, 6.2  1.4, and 4.6  0.7 ng/ml, P 
0.77) were similar in the T1DM, OFF, and NOR
groups, respectively, and increased in T2DM patients
(10.6 2.0 ng/ml) according to the increased body mass
index. -TNFR2 concentrations (1.4  0.1, 1.5  0.1,
1.4  0.1, and 1.3  0.1 ng/ml, P  0.44) were not
different in the T1DM, T2DM, OFF, and NOR groups,
respectively.
Effects of Metabolic Control
To test whether the above-described metabolic and
endocrine parameters observed in patients with T1DM
may be explained by a different metabolic control,
analysis of data was performed segregating and com-
paring the patients in good (n  5; Hb A1c 7.5%) and
poor (n  13; Hb A1c 	7.6%) metabolic control (Table
Fig. 2. Fasting plasma adiponectin concentration was reduced in
T2DM and OFF compared with NOR. In contrast, fasting plasma
adiponectin concentration was increased in T1DM patients com-
pared with T2DM, OFF, and NOR. Hatched column, T2DM; gray
bar, OFF; open bar, T1DM; filled bar, NOR. ‡P 0.03 vs. NOR; †P
0.05 vs. NOR.
Fig. 1. Insulin resistance and intramyocellular lipid (IMCL) content.
Top: glucose metabolic clearance rate (MCR) was shown to be re-
duced in both fasting and insulin-stimulated states in type 1 diabetes
(T1DM) and in the insulin-stimulated state in T2DM and in insulin-
resistant T2DM offspring (OFF) compared with healthy individuals
without T2DM (normal, NOR). Middle: IMCL content was increased
in the soleus muscle of T1DM, T2DM, and OFF compared with NOR,
whereas a significant IMCL content in the tibialis anterior was found
only in T1DM. Bottom: summary of the relationship between MCR
and soleus IMCL content. This relationship was best fitted with a
logarithmic function (R2  0.27, P  0.001). Hatched bars (top and
middle) and open triangles (bottom), T2DM; gray bars and squares,
OFF; open bars and squares, T1DM; filled bars and squares, NOR.
*P  0.001 vs. NOR; †P  0.05 vs. NOR.
E1177IMCL CONTENT IN T1DM
AJP-Endocrinol Metab • VOL 285 • DECEMBER 2003 • www.ajpendo.org
 at Facolta M
edicina Veterinaria on O
ctober 8, 2012
http://ajpendo.physiology.org/
D
ow
nloaded from
 
2). Those in good metabolic control showed a higher
insulin-stimulated glucose MCR (P  0.05) in associa-
tion with lower soleus IMCL content (P  0.05). In
contrast, no effect was observed on the plasma adi-
ponectin concentration.
Regression Analysis
The glucose MCR was inversely associated with the
IMCL soleus content (Fig. 1, bottom, R2  0.27, P 
0.001) and plasma free fatty acid levels (R2 0.25, P
0.01), and these relationships were best fitted with a
logarithmic curve. The associations of glucose MCR
with the soleus IMCL content and plasma free fatty
acids were maintained separately in the study groups
of normal-weight individuals (OFF, T1DM, NOR) but
were not in the patients with T2DM (R2  0.15, P 
0.23). The association of Hb A1c with glucose MCR
(R2 0.27, P 0.04) and both soleus (Fig. 3: R2 0.57,
P  0.001) and tibialis anterior (R2  0.37, P  0.02)
IMCL content was found only in the group of patients
with T1DM. No associations were found between pa-
rameters of insulin sensitivity and the titers of the
immunologic markers of T1DM (anti-GAD, -ICA, and
-IA2 antibodies). No association was found between
adiponectin and the glucose MCR or the disappearance
rate separately in each study group; a significant rela-
tionship was also lacking when individual data were
plotted all together. When data regarding the T1DM
patients were excluded and the analysis was limited to
T2DM, OFF, and NOR subjects, a significant relation-
ship was close to being reached (R2  0.21; P  0.07).
No association was found between adiponectin and
endogenous glucose production in the fasting state or
with the percent suppression of endogenous glucose
production during the clamp study.
DISCUSSION
There were two novel findings in the present study.
1) An increased amount of IMCL content was found in
patients with T1DM similar to what was observed in
patients with T2DM and in the offspring of T2DM
parents (Fig. 1, middle), and this alteration was asso-
ciated with impairment of insulin sensitivity (Fig. 1,
bottom). 2) Increased plasma adiponectin concentra-
tions were found in insulin-resistant T1DM patients in
contrast to the reduced levels found in insulin-resis-
tant T2DM and OFF patients (Fig. 2).
Whole body insulin resistance was found to be asso-
ciated with increased IMCL content in normal subjects
(25, 42), offspring of T2DM parents (23, 35), individu-
als with HIV infection and lipodystrophy due to anti-
retroviral therapy (14, 27), and patients affected by
T2DM and obesity (41). Insulin resistance is to some
extent genetically inherited (38) and in the above-
described populations is strongly related to abdominal
fat independent of total adiposity (29). In contrast,
abdominal obesity, lipids, and androgens were not able
to explain insulin resistance in young women with
T1DM (15). The findings of this work therefore high-
light the importance of IMCL content as a reliable
marker of insulin resistance not only in T2DM but also
in T1DM patients, as is also suggested by a previous
study in which muscle triglyceride was assessed using
the biopsy technique (12). In T2DM and obesity, the
abnormal IMCL accretion may be determined by an
unbalanced muscular fatty acid uptake, fatty acid ox-
idative disposal, and intramuscular lipogenic activity
(24, 34) before the development of overt hyperglycemia.
In T1DM, we found in this work a remarkable relation-
ship between the soleus and tibialis anterior IMCL
content and Hb A1c (Fig. 3). It may be speculated that,
in these patients, the chronic hyperglycemic state may
be relevant in the mechanisms of exaggerated IMCL
accumulation. In the skeletal muscle cell, the sus-
tained hyperglycemia (with or without high fatty acid
availability) may determine a profound stimulation of
acetyl-CoA carboxylase; this in turn determines a cy-
toplasmic accumulation of malonyl-CoA, which is a
potent inhibitor of the carnitine palmitoyltransferase I
system. This scenario previews a marked reduction of
fatty acid transport inside the mitochondrion, a re-
duced fatty acid oxidative disposal, and a consequent
IMCL accumulation (4), as has also been recently re-
ported in normal healthy individuals (37) during mod-
erately prolonged (5-h) experimental combined hyper-
glycemia (8.7 mmol/l) and hyperinsulinemia (258 pmol/
l). The T1DM patients did not undergo a more
intensive insulin therapy regimen to test whether,
Fig. 3. Relationship between soleus IMCL content and Hb A1c in
T1DM patients is depicted (R2  0.57, P  0.001). Also, tibialis
anterior IMCL content was significantly associated with Hb A1c in
T1DM patients (R2  0.37, P  0.02).
Table 2. Metabolic features of T1DM patients in good
(Hb A1c 7.5%) and poor (Hb A1c 	7.6%)
metabolic control
Good Control Poor Control
n (M/F) 2M/3F 7M/6F
Age, yr 284 322
BMI, kg/m2 21.00.8 22.90.9
Hb A1c, % 6.70.2 9.30.4*
Glucose MCR, mg  kg1  min1 6.91.33 4.650.40†
Soleus IMCL content, AU 717 14823†
Adiponectin, g/ml 233 296
Plasma FFA, mmol/l 0.690.23 0.980.22
Values are means  SE. MCR, metabolic clearance rate; IMCL,
intramyocellular lipid. *P  0.01 vs. Good Control; †P  0.05 vs.
Good Control.
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along with an improvement of the metabolic control
and consequent improvement of peripheral insulin
sensitivity, a reduction of the IMCL content was de-
tectable. Nevertheless, we noticed that, when analysis
of data was performed segregating the T1DM patients
into good (n  5; Hb A1c 7.5%) and poor (n  13; Hb
A1c 	7.6%) metabolic control, those in good metabolic
control showed a higher insulin-stimulated glucose
MCR (P  0.05) in association with lower soleus IMCL
content (P  0.05; Table 2). These findings further
suggest a major role of chronic hyperglycemia in the
induction of abnormal IMCL accretion and develop-
ment of insulin resistance in T1DM and support the
possibility that, when a good glucose homeostasis is
achieved, these abnormalities may, at least partially,
be reversed. Whether the IMCL content was the factor
able to influence directly whole body insulin sensitivity
in humans has recently been challenged by data pub-
lished in athletes (16) and by unpublished observations
in our laboratory in patients with myotonic dystrophy.
These two groups of individuals showed increased or
normal insulin sensitivity in association with in-
creased rather than decreased IMCL content. Also in
this study, we observed that, when data were plotted
separately by groups, muscle IMCL content was
strongly associated with insulin-stimulated glucose
MCR in normal-weight individuals (T1DM, OFF, and
NOR), whereas the association was less pronounced in
the fatter, T2DM patients. In addition, the IMCL con-
tent was similar in patients with T2DM and T1DM
despite a more severe degree of insulin resistance in
T2DM; this fact may be explained by the effects of
other well-known variables such as the different an-
thropometric features of these two groups of patients
(29). It must also be stated that it is now believed that
the accumulation of IMCL is not the direct cause of the
development of insulin resistance but rather an inert
marker of the presence of other lipid intermediates
(diacylglycerol, fatty acyl-CoAs, or ceramide) that have
been directly linked to defects in insulin signaling (13,
18, 30, 39, 43).
The second task of this work was to test whether
plasma levels of adipocyte-derived peptides might be
associated with the development of muscle insulin re-
sistance, as recently suggested by several other inves-
tigators in T1DM. Measurements of fasting plasma
adiponectin, leptin, and -TNFR2 were therefore per-
formed in the study groups. Fasting plasma leptin and
-TNFR2 were comparable among the normal-weight
study groups. Not surprisingly, plasma leptin was in-
creased in T2DM patients in accordance with the
higher body mass index. Plasma adiponectin concen-
tration resulted in being reduced in patients with
T2DM and in the OFF compared with the NOR groups
in accord with other data (20). In contrast, its plasma
concentration resulted in being increased in patients
with T1DM compared with the T2DM and OFF sub-
jects but also compared with the NOR group. Appar-
ently the plasma levels of adiponectin were not differ-
ent when measured in those patients with good com-
pared with those in poor metabolic control (Table 2).
Recently, increased plasma adiponectin concentrations
were described in T1DM (22), but that report was
characterized by a lack of assessment of insulin sensi-
tivity in the study subjects. Supporting our finding of
no major changes of plasma adiponectin levels depend-
ing on the metabolic control, Imagawa et al. (22) re-
ported that intensive insulin treatment was not asso-
ciated with a reduction of plasma adiponectin concen-
tration. To our knowledge, the present work represents
the first report in humans in which increased plasma
adiponectin concentrations are associated with an in-
sulin-resistant state in contrast with other classical
insulin resistance conditions (T2DM and obesity), in
which its level is reduced. Another condition in hu-
mans in which adiponectin showed unexpected behav-
ior was recently reported in normal healthy individuals
in whom the improvement of insulin sensitivity ob-
tained by means of physical exercise training was not
paralleled by an increment of the plasma adiponectin
concentration (21). These findings therefore demon-
strate that the role of adiponectin in the regulation of
peripheral insulin sensitivity in vivo in humans is still
unclear. Besides the relationship between adiponectin
and peripheral insulin sensitivity, it is known that
adiponectin has major effects at the liver site on glu-
cose (7) and fatty acid (45) metabolism. With respect to
glucose metabolism, the T1DM patients, along with
increased circulating adiponectin levels, had increased
fasting endogenous glucose production rates and a cer-
tain degree of resistance to the inhibitory effects of
insulin, even if these parameters were not associated
with the adiponectin levels and even if the insulin dose
used in the present protocol was not appropriate for the
assessment of hepatic insulin sensitivity. With respect
to fatty acid metabolism, the intrahepatic fat content
was not measured in these patients because the study
was focused on peripheral insulin sensitivity. We can-
not, therefore, exclude the possibility that the in-
creased plasma adiponectin concentration found in
T1DM patients may be explained by metabolic features
at the liver site.
In conclusion, this work demonstrates that, in pa-
tients with T1DM, as well as in patients with T2DM
and in individuals at higher risk of developing T2DM,
increased IMCL content is a marker of peripheral
insulin resistance, suggesting that inherited and/or
acquired metabolic alterations may be predisposing
factors for abnormal accretion of IMCL content and of
specific IMCL intermediates able to induce insulin
resistance. This study also suggests that maintenance
of normal IMCL content is important for preserving
insulin sensitivity, not only in patients with T2DM but
also in patients with T1DM, and that recommenda-
tions for a proper lifestyle and possibly the use of drugs
capable of reducing the IMCL content may represent a
therapeutic tool useful to improve glucose homeostasis
also in T1DM patients.
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